Recent developments in recombinant DNA technology have led to the large-scale production of human erythropoietin and to the demonstration that it is effective in the treatment of renal and possibly some other anaemias. This has lent a new impetus to studies of the pathophysiology and pharmacology of the hormone which is reflected in this report of the proceedings of a meeting held in Liibeck in June 1988. In 15 papers, all from European centres, the broad topics covered are erythropoietin's physiology and chemistry, the patho- physiology of erythropoiesis and the use of erythropoietin in the treatment of anaemia. Several of the papers include up-to-date reviews of the literature. The field is now expanding rapidly, and this volume, though not comprehensive, usefully points up many areas of recent understanding as well as others of continuing un- certainty. Overall, it contains material likely to be of interest to biochemists and experimental haematologists as well as to phar- macologists, clinical haematologists and nephrologists.

Edited by two leading orthopedic surgeons who are specialists in the treatment of hemophilia, Orthopedic Surgery in Patients with Hemophilia shows all the surgical techniques needed for surgical treatment of musculoskeletal complications of hemophilia. A practical guide, designed for use on the ward or in the office, this book draws on the experience of numerous specialists worldwide, from developed and developing countries. As well as orthopedic surgery, it also covers research, hematology, and rehabilitation. Although of primary interest to the orthopedic surgeon, rheumatologist, and physiotherapist, this book will also be relevant to the hematologist responsible for the care of the hemophiliac patient.

Active specific immunotherapy is a promising but investigational modality in the management of cancer patients. Currently, several different cancer vaccine formulations such as peptides, proteins, antigen-pulsed dendritic cells, whole tumor cells, etc. in combination with various adjuvants and carriers are being evaluated in clinical trials (1-3). To determine the optimal cancer vaccine strategy, a surrogate immunological end-point that correlates with clinical outcome needs to be defined, since it would facilitate the rapid comparison of these various formulations. Traditional immunological assays such as ELISA, proliferation and cytotoxicity assays can detect immune responses in vaccinated patients but are not quantitative. In contrast, novel assays such as enzyme-linked immunospot (ELISPOT) assay, intracellular cytokine assay and tetramer assay can quantitate the frequency of antigen-specific T cells. Of these, the ELISPOT assay has the 5 lowest detection limit with 1/10 peripheral blood mononuclear cells (PBMC) and has been determined to be one of the most useful assays to evaluate immune response to cancer vaccines (4). However, the IFN-? ELISPOT assay is not an exclusive measure of cytotoxic T-lymphocyte (CTL) activity as non-cytotoxic cells can also secrete IFN-?. Additionally, CTL with lytic activity do not always secrete IFN-? (5). A more relevant approach to assess functional activity of cytotoxic lymphocytes would be to measure the secretion of molecules that are associated with lytic activity. One of the major mechanisms of cell-mediated cytotoxicity involves exocytosis of cytoplasmic granules from the effector toward the target cell.

What we now call 'deep venous thrombosis' (DVT) has been elucidated by a diversity of investigative approaches during the past four centuries. The authors of this book survey the history of the field and ask: why has one of these perspectives - the haematological/biochemical - come to dominate research into the causation of DVT during the past 50 years and to exclude alternatives? In answering this question, the authors show that the current consensus model is conceptually flawed.

A large number of chemical agents are known which affect blood and blood-forming organs. The purpose of this volume is to review the sig- nificant advances made over the past several years regarding such chemical agents. The purification, biological action, and therapeutic implications of several widely used hematopoietic growth factors such as interleukin 3 (IL-3 or multi-CSF), granulocyte/macrophage colony stimulating factor (GM-CSF), granulocyte colony stimulating factor (G-CSF), colony stimu- lating factor (CSF-I or M-CSF), thrombopoietin, and erythropoietin are included in this volume. These factors are important in regulating several hematopoietic cell lines such as neutrophils, monocytes, eosinophils, macrophages, megakaryocytes, platelets, and erythrocytes. People are exposed daily to numerous toxic chemical substances present in our environment which produce a suppression of erythropoiesis, myelo- poiesis, lymphocytopoiesis, and megakaryocytopoiesis. Attempts have been made in this volume to assess the therapeutic role of some of the hematopoietic factors such as erythropoietin in the anemia of end stage renal disease, as well as colony stimulating factors in other hematopoietic abnormalities. In addition, some of the chemical factors in our environment which suppress major hematopoietic lineages stimulated by erythropoietin, macrophage colony stimulating factor, granulocyte colony stimulating factor, interleukin I-alpha, interleukin I-beta, and interleukins 2, 3, 4, 5, 6, 7, and 9 are also included. An updating of the mechanism of action of each of these factors on the major hematopoietic lineages is covered.

The cloning of hemopoietic cells in semisolid medium began some 12 years ago, and when colonies of T = and B = lymphocytes were grown by several groups last year, the last major subclasses of hemopoietic cells had been successfully cultured in vitro. The time seemed appropriate to write a short general account of this exciting new area of hematology, emphasizing particularly the potential value of these new techniques for direct studies on patients with leukemia and allied diseases. I had hoped to refer to, or at least record, every paper published in this field, but the literature proved to be larger than I had realized, and furthermore, some areas were so active that chapters had to be rewritten over a period of less than a year. I regret that .what follows is an incomplete account and no doubt, by the time this book becomes available, the material will be even more out of date. However, I have described the basic techniques in some detail and have tried, where possible, to explain how and why the techniques can fail. It is already possible to see patterns, perhaps even principles, emerging from this work which may well be applicable to other cell populations. These have been emphasized in the text in an attempt to make this review as creative as possible."

MSC (mesenchymal stem cells) have been reported to initiate revascularization after injury, to facilitate engraftment of blood-forming stem cells, and to reduce the incidence of graft-vs. host disease through their immune-suppressive qualities. Finally, bone marrow-derived MSC have been reported to home to areas of solid tumor revascularization, and thus may be used as delivery vehicles to target ablative agents into dividing tumor cells. Recently the characteristics of human MSC from adipose (fat) tissue have also been identified. The possibility of repairing tissues, speeding stem cell engraftment, and targeting solid tumors for specific killing, using MSC easily harvested from bone marrow, or better yet, from unwanted fat tissue, holds broad appeal, and is an intriguing possibility that could have dramatic effect on health care.

This book has information on how to isolate, grow, and characterize MSC from marrow and fat, and gives important insight into how these cells may be used for gene delivery and cellular therapies in the future. Updates on emerging clinical trials are given.

A rapid increase in our understanding of the biology of platelets and their role in disease in recent years has been paralleled by increasing successes with established platelet-modifying therapies in many clinical conditions. This text focuses on the clinical role of platelets in a wide variety of haematologic, cardiovascular and other disorders, providing a practical, clinically relevant handbook for all clinicians and researchers interested in platelets and their role in disease. Covering platelet physiology, bleeding disorders, thrombotic disorders and antithrombotic therapy. Chapters cover all the conventional and less conventional aspects of platelet involvement in disease, with an emphasis on recent clinical developments. Clear take home messages have been included in each chapter to aid clinical practice. With contributions from leading experts across three continents, Platelets in Hematologic and Cardiovascular Disorders is an up-to-date, well illustrated, practical resource for everyone involved in clinical practice with platelet disorders.

Leading international experts contribute to this selection of reviews covering the merging fields of growth factors, differentiation factors, and cytokines. These appear to play fundamental roles in a wide variety of physiological and pathophysiological processes that include the regulation of growth in normal and malignant cells, embryogenesis, the immune response, wound healing, inflammation, and atherogenesis. The major aspects of recent research and development are discussed, providing an important update in this pioneering field.

th This book contains most of the papers presented at the Iy Inter- national Symposium on Bone Circulation which was held in Tou- louse, France, in September of1987. The symposium was attended by over 200 specialists from 17 different countries. Some of them were in Toulouse for the fourth time to discuss their favourite topic of study and research: bone circulation, its exploration, its pathol- ogy. Many, including a group of Japanese orthopaedic surgeons, were present for the first time, delighted to meet the authors of papers they had read. There were more than 100 oral presentations and posters, but many meaningful informal discussions took place both in and outside of the auditorium, in the hall and during meals. The organizers wished to maintain a balance between funda- mental themes and subjects of clinical and practical interest. This balance was accomplished: recent developments including scintig- raphy, magnetic resonance imaging and bone grafts played just as important a part as more sophisticated topics such as the evalua- tion of the blood flow rate in animal bone tissue. Thus, as did the previous symposia, this book aims to present a progress report on developments during the last 5 years in the study of bone circulation. We wish to thank all those who helped and encouraged us throughout the organization of the congress, especially C. Ar- noldi, M. Brookes, R. Burkhardt, L. Coutelier, S.P.F. Hughes, P. Kehr, J.P. Jones, A. Trias, K.Ono, T. Yizkelety and G.J.

Contents: Introduction and Overview Lymphopoietic Growth Factors: Pathophysiology of T-Cell Mediated Shock Induced by Bacterial Superantigens - Natural Killer Cells and Interleukin-2-Activated Killer Cells - TumourImmunogenicity Induced by Exogenous Interleukins - Cytokine Gene Therapy of Cancer - Analysis of T-Cell Receptor Variability in Tumour Infiltrating Lymphocytes - Clinical Studies with Interleukin-2: An Overview - Clinical Trials with Local Administration of Lymphopoietic Growth Factors - Clinical Trials with Interlaukin-2. The Rome Experience. Haematopoietic Growth Factors: Lymphohaematopoietic Growth Factor Use in Lung Cancer Patients - Clinical Trials with Haematopoietic Growth Factors and Peripheral Blood Stem Cells

One of the most fascinating tools at the disposal of the molecular biologist is the medical clinic. The responsibilities of those who provide health care do not stop when they give optimal care to the individual patient and train their successors adequately. They also are under the obligation to obtain maximal information from every case they treat in order to reach a better understanding of the underlying illness in order to improve therapeutic results in the next patient. Fundamental research in pathological material is therefore a medical must as well as an opportunity for scientific work. The scientist working in this field can profit from nature's unasked for experiments, which are encountered by his medical colleagues in their clinical material. There are many examples of subjects of study - for instance hemoglobins and immunoglobulins - which started in a medical context and gradually developed into a field of prime interest for the molecular biologist. The study of blood coagulation is one of the younger areas of this kind.

An overview of diagnosis and current management of myelodysplastic syndromes.

- Reviews the performance of the pharmacological treatments currently available and analyses the potential for new treatments
- High quality clinical photos and figures to enhance descriptions and improve reader comprehension
- Useful reference text for healthcare professionals needing to know more about myelodysplastic syndromes

David Kuter and a host of leading international researchers summarize in one volume all the knowledge of thrombopoietins (TPO) available today. The distinguished experts review the history of the search to discover TPO, describe the molecular and biological characteristics of this new molecule, and present the results of the preclinical animal experiments that will guide clinical use of this new hormone. Along the way they provide the most recent and comprehensive guide to the biology of megakaryocytes and platelets.

"The Blood Group Antigen FactsBook" has been an essential resource in the hematology, transfusion and immunogenetics fields since its first publication in the late 1990s.Thethird editionof "The Blood Group Antigen FactsBook" has been completely revised, updated and expanded to cover all 33 blood group systems. It blends scientific background and clinical applications and provides busy researchers and clinicians with at-a-glance information on over 330 blood group antigens, including history and information on terminology, expression, chromosomal assignment, carrier molecular description, functions, molecular bases of antigens and phenotypes, effect of enzymes/chemicals, clinical significance, disease associations and key references.
Includes over 330 entries on blood group antigens in individual factsheetsOffers a logical and concise catalogue structure for each antigen in an improved interior design for quick referenceWritten by 3 international experts from the field of immunohematology and transfusion medicine"

This unique publication explores diverse themes relating to thrombosis and embolism, from basic research at cell and molecular level to the actual care, prevention, and treatment of diverse categories of patients suffering from such diseases. Chapters cover a variety of topics including thrombosis and embolism in surgical patients, cancer patients, pregnant women and children and adolescents, as well as treatment of the conditions by traditional anticoagulants, novel oral anticoagulants, thrombolytic therapy, endovascular treatment and embolectomy. Readers may explore cutting edge research, recommendations from major societies, contemporary guidelines, areas of controversy and directions for ongoing and future research. The book features comprehensive information ranging from molecular mechanisms of diseases to the clinical features, diagnosis, and therapeutic regimens for treating a variety of clinical conditions. It has a broad appeal to scientists and research students as well as busy clinicians engaged in patient care, who will all find something important and useful amongst these carefully selected chapters.

Welcome to the City of Groningen, the center of the North of the Netherlands. Groningen is proud of the long lasting tradition of scientific symposia organised by the Sanquin Blood Bank. These Sanquin International Symposia on Blood Transfusion have become a true traditional event in Groningen, marking the early academic year and have contributed to the specific reputation of Groningen and its University in the scientific field of Transfusion Medicine. The growing tradition has also contributed to initiatives of both University, Province and the City of Groningen to bring science and industry together - BioMedCity Groningen. Such repu- tion does not just happen, but is the result of creative and scientific leadership, of vision and an open mind, to explore in a team spirit horizons. Groningen is particularly proud of this reputation thanks to its leadership, the Sanquin Blood Bank North-East. This year in particular the theme chosen some two years ago is extremely timely as it illustrates the activities and scientific interest of an integrated team which includes our regional Sanquin Blood Bank North-East and fits in the City initiatives within the concept of BioMedCity, Groningen.

This is a comprehensive textbook of Hodgkin's and non-Hodgkin's lymphomas written by leaders in the field of childhood lymphomas. It includes clinical, pathologic and molecular biology of each subtype of lymphoma. The pathology chapters are comprehensive and include excellent photographs. The book is at the level of subspecialists in pediatric hematology and oncology, radiation oncology, pediatric surgery and hematopathology.

The colony-stimulating factors (CSFs) are the major regulators in the body of the production and activity of two types of white blood cells--granulocytes and macrophages. CSFs are used by clinicians to treat patients with damaged immune systems, for example, as a result of chemotherapy. This book provides a detailed and up-to-date account of the discovery of the CSFs, their structure, molecular biology and cellular receptors, the biology of the CSFs in vivo and in vitro, and their present and future clinical applications. Written by two of the pioneers in the discovery of CSFs, it is a clear and well illustrated survey of the history, current knowledge and future directions of this exciting field of investigation, and serves also as a guide to the more general areas of growth factor and cytokine research. It will prove an invaluable review for cell biologists interested in how growth factors act on the body, as well as for clinicians applying the fruits of modern biotechnology to improved patient care.

Now more than ever, thrombotic and thromboembolic disorders as well as related diseases such as malignancies, arteriosclerosis, diabetes mellitus, hypertension, and obesity are the leading causes of morbidity and mortality. They have become urgent medical problems with serious economic consequences in industrialized and devel- ing countries alike. At the same time, the impact of molecular biology and genetics on our understanding of thrombosis and hemostasis is rapidly growing stronger as well as our knowledge of regeneration and development of specific tissues, organs, and embryos. Researchers are also constantly learning more about cardiovascular diseases as well as regulatory mechanisms for various intrinsic and extrinsic stimuli in viable tissues. In this volume, our intention has been to present the latest relevant information in molecular biology and genetics as well as the clinical implications of a better understanding of pathophysiology, novel diagnostic methodologies, and therapeutic applications for new methods of prevention in thrombosis/hemostasis and related disorders, including atherosclerosis. The dramatic advances in knowledge of thrombosis/hemostasis and vascular biology since the first publication of Recent Advances in Thrombosis and Fibrinolysis, edited with Japanese colleagues, in 1991, have required extensive revision in order to highlight and review recent progress in the field. The editors also gratefully welcome the seven distinguished non Japanese authors, who, with their valuable contributions on subjects beyond the coverage by Japanese authors, have made this new edition truly international.

The standard-setting text in oncology for 40 years, DeVita, Hellman and Rosenberg's Cancer: Principles and Practice of Oncology, 12th Edition, provides authoritative guidance and strategies for managing every type of cancer by stage and presentation. Drs. Vincent T. DeVita, Jr., Theodore S. Lawrence, and Steven A. Rosenberg oversee an outstanding team of expert contributing authors who keep you up to date and fully informed in this fast-changing field. This award-winning reference is also continually updated on Health Library and VitalSource platforms for the life of the edition. Integrates basic science into individual cancer chapters for more efficient reference Features quarterly updates that include late-breaking developments in oncology such as new drugs and clinical trials, as well as new case studies and interactive algorithms Offers balanced, multidisciplinary advice from a surgeon, a medical oncologist, and a radiation oncologist Provides updated content on immunotherapy and genetics throughout Includes important related topics such as cancer screening and prevention, palliative care, supportive oncology, and quality of life issues Now available in a convenient single volume, or a seven-multivolume option for portability and ease of use Enrich Your eBook Reading Experience Read directly on your preferred device(s), such as computer, tablet, or smartphone. Easily convert to audiobook, powering your content with natural language text-to-speech.

The first book to cover both basic science and clinical research, providing a comprehensive review of the current knowledge on cytokines and cancer. Written by leading figures in the field of cytokine biology and cytokine therapeutics.

Expert physicians and clinical researchers summarize and explain all the recent advances in the biology and treatment of bone marrow-based malignancy. On the biological side, the authors show the characteristics of the malignant cell and describe the significant roles played by oncogenic changes, chromosomal anomalies, Kaposi's sarcoma herpes virus, and cytokines. New epidemiological findings and prognostic factors are also analyzed. On the clinical side, the authors provide a comprehensive review of conventional treatment regimens, as well as a discussion of newer experimental approaches involving immunologic targeting, inhibitors of drug resistance, and antitumor agents.

Building on the considerable expertise of the dysproteinemia unit at Mayo Clinic, this book spans the gamut from multiple myeloma, the most frequent and most serious of the monoclonal gammopathies, to the rarest related disorders. Laboratory evaluation, associations with nonhematologic disorders, monoclonal gammopathies of undetermined significance, the more obscure plasma cell dyscrasias, amyloidosis, other immunoglobulin deposition disorders, Waldenstrom macroglobulinemia, and Fanconi anemia are among the topics covered. Naturally, particular attention is paid to multiple myeloma: history, pathogenesis, clinical and laboratory diagnosis, modern therapy, and prognosis. Subsets of multiple myeloma such as solitary plasmacytoma, extramedullary plasmacytoma, and plasma cell leukemia are reviewed. This volume is designed to serve as a long-lasting reference for clinicians and scientists involved in the management of multiple myeloma and associated disorders."